DNV Capital

DNV Capital concentrates on venture capital investment in start-up period and growth period, the directions of investment cover: medical treatment and health industry, AI, Internet of things, and cloud computing.

Dana Ren

Vice President

9 past transactions

Binhui Biotech

Series B in 2022
Wuhan Binhui Biotechnology Co., Ltd. was established in 2010. The company is located in the Optics Valley Bio City of Donghu National Independent Innovation Demonstration Zone. The company is committed to providing innovative products and services for the field of oncology integration (including diagnosis and treatment), and developing products and services that have independent intellectual property rights and can compete with other manufacturers on the international stage.

CANbridge Pharmaceuticals

Series E in 2020
CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.

Hinova Pharma

Series C in 2020
Hinova Pharma is an innovative drug research and development manufacturer that provides users with compound HC-1119 androgen receptor (AR) antagonism by using drug discovery systems such as medicinal chemistry, biological screening, process research, quality research, clinical reporting, and clinical research. Drugs, HC-1102 androgen receptor inhibitors and other products, for the treatment of advanced prostate cancer and breast cancer.

Geneseeq

Series B in 2017
Established in 2008, Geneseeq is an industry leader in Next-Generation Sequencing (NGS) fully committed to the research and clinical translation of NGS Genetic Sequencing in the field of personalized medicine. Geneseeq’s world-leading laboratories have successfully passed China’s National Center of Clinical Laboratories(NCCL) External Quality Assessment(EQA), College of American Pathologists(CAP) PT, European Molecular Genetics Quality Network(EMQN) PT, and received 3rd party medical laboratory and clinical PCR amplification laboratory qualifications.

Sonendo

Series E in 2016
Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely used endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.

JFK Biotech

Angel Round in 2015
JFK Biotech develops products for molecular diagnosis and rapid self-test technology. They also offer a series of products for early screening, early diagnosis, and early treatment of pulmonary nodules, lung cancer, COPD, asthma, airway inflammation, and airway infection.

AngioSlide

Series E in 2015
Angioslide, founded in 2005 by Eran Hirszowicz and Amos Nahir, is a privately-held medical device company. The company has developed a unique Embolic Capture Angioplasty™ (ECA) device family that combines standard balloon angioplasty with debris removal capabilities through its suction mechanism. Physicians using the PROTEUS™ device can now capture and remove embolic particles during angioplasty procedures.

TruTag Technologies

Series A in 2014
TruTag Technologies, Inc. is a leading authentication and technology solution provider serving businesses and governments around the world. TruTag has the most advanced precision-fabricated, cGMP nano-porous silica manufacturing operation in the world for product authentication across a broad range of industries including pharmaceuticals, food, consumer products, and industrial & electronic parts. TruTag’s authentication platform is complemented by its’ advanced hyperspectral imaging technology, which is focused on providing powerful next-generation inline quality assurance solutions and diagnostics. TruTag Technologies has been recognized by the SPIE Prism Awards, the Edison Awards, Fast Company, R&D 100, and was selected a Technology Pioneer by the World Economic Forum as one of the most influential technology companies in the world.

Vessix Vascular

Series B in 2011
Vessix Vascular, Inc. (formerly known as Minnow Medical, Inc.). Vessix is a privately-held pre-revenue stage company developing novel radiofrequency balloon catheter technology. The Company's initial product, the ZCath® System, has a CE Mark for use in reducing plaque in peripheral leg arteries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.